Characterization of immunogenic properties of polyclonal T cell vaccine intended for the treatment of rheumatoid arthritis.
Two-staged technology for obtaining polyclonal T cell vaccine intended for the treatment of rheumatoid arthritis is described. Stage 1 includes antigen-dependent cultural selection of patient's T cells and stage 2 consists in their reproduction in the needed amounts by nonspecific mitogenic stimulation. T cell vaccination induces an effective specific anti-idiotypic immune response against T cells reactive to joint antigens. Vaccine therapy significantly reduces plasma level of IFN-gamma and increases IL-4 level. The results indicate immunological efficiency and safety of polyclonal T cell vaccine in patients with rheumatoid arthritis.
Ivanova
I P
IP
Institute of Clinical Immunology, Siberian Division of Russian Academy of Medical Sciences, Novosibirsk. irinaiki@rambler.ru
Seledtsov
V I
VI
Seledtsov
D V
DV
Samarin
D M
DM
Seledtsova
G V
GV
Herzsog
O A
OA
Kozlov
V A
VA
D019264:Adoptive Transfer / Q000379:methods; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000276:immunology* / Q000628:therapy; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology; D015847:Interleukin-4 / Q000097:blood / Q000276:immunology; D007592:Joint Diseases / Q000097:blood / Q000276:immunology / Q000628:therapy; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D016896:Treatment Outcome; D014612:Vaccines / Q000276:immunology*
D014612:Vaccines; D015847:Interleukin-4; D007371:Interferon-gamma